Feedback Last updated on Jan 20, 2024 Photo by Tapish / Unsplash Previous Publications Update # 44 Next NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
